161 related articles for article (PubMed ID: 2540560)
1. DHPG treatment of kidney transplant recipients with severe CMV infection.
Lang P; Buisson C; Rostoker G; Ben Maadi A; Fruchaud G; Deforge L; Chopin D; Abbou C; Romano P; Fleury J
Transplant Proc; 1989 Feb; 21(1 Pt 2):2084-6. PubMed ID: 2540560
[No Abstract] [Full Text] [Related]
2. Treatment of cytomegalovirus infections in renal transplant recipients with 9-(1,3-dihydroxy-2-propoxymethyl) guanine.
Cantarovich M; Hiesse C; Lantz O; Fassi-Fihri S; Charpentier B; Fries D
Transplantation; 1988 Jun; 45(6):1139-41. PubMed ID: 2837848
[No Abstract] [Full Text] [Related]
3. Massive cytomegalovirus pneumonia and myocarditis in a renal transplant recipient: successful treatment with DHPG.
Shabtai M; Luft B; Waltzer WC; Anaise D; Rapaport FT
Transplant Proc; 1988 Jun; 20(3):562-3. PubMed ID: 2837853
[No Abstract] [Full Text] [Related]
4. Treatment of cytomegalovirus pneumonia in heart transplant recipients with 9(1,3-dihydroxy-2-proproxymethyl)-guanine (DHPG).
Watson FS; O'Connell JB; Amber IJ; Renlund DG; Classen D; Johnston JM; Smith CB; Bristow MR
J Heart Transplant; 1988; 7(2):102-5. PubMed ID: 2835468
[TBL] [Abstract][Full Text] [Related]
5. DHPG (Gancyclovir) improves survival in CMV pneumonia.
Mai M; Nery J; Sutker W; Husberg B; Klintmalm G; Gonwa T
Transplant Proc; 1989 Feb; 21(1 Pt 2):2263-5. PubMed ID: 2540565
[No Abstract] [Full Text] [Related]
6. DHPG effectively treats CMV infection in heart and heart-lung transplant patients: a preliminary report.
Icenogle TB; Peterson E; Ray G; Minnich L; Copeland JG
J Heart Transplant; 1987; 6(4):199-203. PubMed ID: 2822880
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of cytomegalovirus disease with 9-(1,3-dihydroxy-2-propoxymethyl guanine).
de Hemptinne B; Lamy ME; Salizzoni M; Cornu C; Mostin J; Fevery J; De Groote V; Otte JB
Transplant Proc; 1988 Feb; 20(1 Suppl 1):652-5. PubMed ID: 2831645
[No Abstract] [Full Text] [Related]
9. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
10. Tolerance and efficacy of ganciclovir in the treatment of cytomegalovirus infections in immunosuppressed patients.
Ho WG; Winston DJ; Champlin RE
Transplant Proc; 1989 Feb; 21(1 Pt 3):3103-6. PubMed ID: 2539690
[No Abstract] [Full Text] [Related]
11. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment with ganciclovir of disseminated cytomegalovirus infection after liver transplantation.
Stein DS; Verano AS; Levandowski RA
Am J Gastroenterol; 1988 Jun; 83(6):684-6. PubMed ID: 2837082
[TBL] [Abstract][Full Text] [Related]
13. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients.
Schmidt GM; Kovacs A; Zaia JA; Horak DA; Blume KG; Nademanee AP; O'Donnell MR; Snyder DS; Forman SJ
Transplantation; 1988 Dec; 46(6):905-7. PubMed ID: 2849818
[No Abstract] [Full Text] [Related]
14. Successful treatment of severe cytomegalovirus infections with ganciclovir and CMV hyperimmune globulin in liver transplant recipients.
D'Alessandro AM; Pirsch JD; Stratta RJ; Sollinger HW; Kalayoglu M; Belzer FO
Transplant Proc; 1989 Jun; 21(3):3560-1. PubMed ID: 2545018
[No Abstract] [Full Text] [Related]
15. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
16. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
[TBL] [Abstract][Full Text] [Related]
17. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
Shah T; Lai WK; Mutimer D
Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
Ahsan N; Holman MJ; Yang HC
Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
[TBL] [Abstract][Full Text] [Related]
20. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients.
Ozaki KS; Câmara NO; Nogueira E; Pereira MG; Granato C; Melaragno C; Camargo LF; Pacheco-Silva A
Clin Transplant; 2007; 21(5):675-80. PubMed ID: 17845644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
